Vimarsana
Biggest News Aggregation in the World

Page 27 - Loss Attributable News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Loss Attributable. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Loss Attributable Today - Breaking & Trending Today

Jowell Global Ltd. Announces Full Year 2022 Financial Results - Vimarsana News

Jowell Global Ltd. Announces Full Year 2022 Financial Results

-- Full Year Revenue of $210.0 million, up 22.9% year-over-year -- SHANGHAI, May 15, 2023 /PRNewswire/ -- Jowell Global Ltd. , a leading cosmetics, health and nutritional supplements, and household... | June 12, 2023

Coca Cola Bottlers Japan : Consolidated Financial Summary for the First Quarter Ended March 31, 2023 (IFRS) - Vimarsana News

Coca Cola Bottlers Japan : Consolidated Financial Summary for the First Quarter Ended March 31, 2023 (IFRS)

This flash report is unaudited and a translation of the Japanese language version. Consolidated Financial Summary for ... | May 12, 2023

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 - Vimarsana News

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

- Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline - Advancing registration program for SerpinPC to treat hemophilia B; Enrolling subjects in

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023 - Vimarsana News

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023

– Strong clinical momentum and cash runway into 2026 to support multiple clinical readouts across pipeline – Advancing registration program for SerpinPC to treat hemophilia B; Enrolling... | May 12, 2023

Theriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results - Vimarsana News

Theriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

- Continued to enroll patients in VIRAGE, the Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma - - Presented data from